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Abstract 
Using ultrafiltration by centrifugation we have isolated the free, unbound fractions of insulin-like growth factor I and II (free IGF-I and IGF-II) 
in human serum. In thii way near in vivo conditions could be maintained before and during isolation. The recovery was 80 to 100% in the ultraliltrates, 
which contained no detectable amounts of IGF-binding proteins (IGFBPs) as measured by Western ligand blotting and IGFBP-I and IGFBP3 
immunoassays. The concentration of free peptides was measured in two ultrasensitive non-competitive IGF-I and IGF-II time-resolved fluoroimmu- 
noassays. We found that (i) equilib~um between free and prote~-~rnplex~ IGF was strongly dependent on re~s~biis~ent of in vivo conditions 
(temperature, pH, ionic milieu and dilution); (ii) metabolic events (glucose load and fasting) caused significant changes in free IGF-I and IGF-II 
levels without concomitant changes in total circulating levels of IGFs; (iii) in 49 healthy adult subjects (20 to above 60 years) free IGF-I was inversely 
related to age and ranged from 950 + 150 rig/l (mean z!z S.E.M.) (20-30 years) to 410 + 70 r&l (>60 years). The relative percentage was, however, 
unchanged, being 0.38 + 0.02% of total IGF-I. In contrast, free IGF-II was independent of age, being 1,480 k 80 rig/l (-0.20 f 0.01% of total IGF-II). 
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1. Introduction 
The insulin-like growth factors (IGF-I and IGF-II) 
exist in human serum complexed to specific proteins, the 
insulin-like growth factor binding proteins, of which 6 
are known (IGFBP-1 to IGFBP-6). These proteins are 
believed to modulate IGF-actions by inhibiting or possi- 
bly in some situations enhancing the effects of IGFs on 
target cells [l]. However, by analogy with sex and adre- 
nal steroids and thyroid hormones, the unbound moiety 
may be the dominating fraction for the biological activity 
[2]. The methods which have been used to obtain an 
estimate of the concentration of free IGF-I and IGF-II 
include ultracentrifugation [2], size-exclusion gel chrom- 
atography (SEC) [3-71, high pressure liquid chromatog- 
raphy (HPLC) [8-l l] and reverse phase chromatography 
[ 121. Recently, immunochemical analyses based on direct 
determination of free IGF-I in serum using antibodies 
directed against the unbound peptide have been de- 
scribed [13,14]. However, the fraction of unbound IGF-I 
determined with these methods has varied considerably: 
from undetectable levels [2,7,9] to 19% of total IGF-I [4]. 
Free IGF-II has been estimated to be about 1% of total 
IGF-II [5]. This diversity is probably due to varying 
degrees of disturban~ of equilibria between free and 
IGFBP-complexed IGF. Maintenance or re-establish- 
ment of in vivo conditions (i.e. temperature, pressure and 
ionic milieu) is impossible using chromatographic sepa- 
*Corresponding author. Fax: (45) 86139023. 
ration, and the influence of sample dilution was un- 
known. Assay-incubation conditions approx~ating in 
vivo milieu are possible in immunochemical analyses. 
However, the interference of antibodies on the equilib- 
rium between the IGFBPs and IGF-I and IGF-II is un- 
predictable and will vary in different samples. 
The aim of the present study was to develop a method 
that under physiological circumstances (temperature, pH 
and ionic composition) isolates the free fractions of IGF- 
I and IGF-II in serum and leaves the equilibrium un- 
changed: this was attained using ultrafiltrates obtained 
by centrifugation at 37°C. The concentrations of total 
and free IGF-I and IGF-II were determined using two 
newly developed ultrasensitive non-competitive time-re- 
solved fluoroi~unoassays (TR-FIAs) 1153. We (i) in- 
vestigated the importance of re-establishing in vivo con- 
ditions before and during separation of free from bound 
peptide; (ii) compared the results with those obtained 
using HPLC separation; (iii) measured the concentra- 
tions of free IGF-I and IGF-II in (patho-) physiolo~cal 
situations, when endogenous IGFBP-1 concentrations 
had been manipulated; and (iv) measured free IGFs in 
healthy volunteers and subjects with abnormal growth 
hormone production (acromegaly and growth hormone 
deficiency (GHD)). 
2. Experimental and results 
All chemicals were of analytical grade, and if not 
otherwise stated, from Merck (Darmstadt, Germany). 
Human serum albumin (HSA) was obtained from 
Behring AG, Marburg, Germany. 
~14-5793/94/$7.~ 0 1994 Federation of European Bi~he~cal Societies. All rights reserved. 
SSDI 0014-5793(94)00602-R 
186 J. Frystyk et al. IFEBS Letters 348 (1994) 185-191 
2.1. IGF-I and IGF-II assays 
Measurement of IGF-I and IGF-II was performed 
by two sensitive non-competitive time-resolved fluoro- 
metric immunoassays (TR-FIAs) based on a modified 
FIA-technique: dissociation-enhanced lanthanide fluo- 
rescence immunoassay (DELFIA) [IS]. Two sets of mon- 
oclonal IGF-I and IGF-II antibodies were used: the first 
was immobilised on microtest-plate wells (IGF-I: MAB 
41, Novo Nordisk A/S, Bagsvaerd, Denmark; IGF-II: 
anti-rat IGF-II IgG, Upstate Biotechnology Inc., NY, 
USA), the second labelled with europium (IGF-I: clone 
02 1, Diagnostic System Laboratories Inc., Webster, TX, 
USA; IGF-II: MAB 73, Novo Nordisk A/S, Bagsvaerd, 
Denmark). Biosynthetic hIGF-I (Amgen Biologicals, 
CA, USA purchased from Amersham Int., Amersham, 
Bucks, UK) and recombinant human IGF-II (Austral 
Biologicals, San Ramon, CA, USA) served as standards. 
IGF-I and LGF-II cross-reactivity in heterologous assays 
was below 0.0002%. The detection limits were 0.0025 
pg/l and 0.010 ,ug/l for the IGF-I and IGF-II assay. The 
operating range was 0.005 ,ug/l to 2.5 pg/l (IGF-I) and 
0.020 &l to 10.0 yg/l (IGF-II), and both calibration 
curves were linear in these intervals. Intra- and inter- 
assay coefficient of variation (CV) were less than 5% and 
10%. Total IGF-I and IGF-II were determined in dupli- 
cates after acid ethanol extraction [ 161 in a final dilution 
of 1: 1,000 (IGF-I) and 1: 2,000 (IGF-II). Free IGF-I and 
IGF-II were determined in ultrafiltrates diluted 1: 11 or 
1:21; ultrafiltrates (2 or 3 per sample) were analyzed in 
single determinations. 
(Amicon Division, W.R. Grace and Co. Beverly, MA, 
USA). Since batch to batch variation (rarely) occurred, 
is was necessary to check each batch for IGF-I and -11 
recovery and IGFBP- 1 retention. 
To remove particles, samples were prefiltered through 
a 0.22 pm filter (Millex-GV, Millipore S.A., Molsheim, 
France) before cent~fugation at 300 x g (1,500 rpm) 
(Hettich Zentrifugen, Tuttlingen, Germany, model 
Rotixa/RP (swinging bucket rotor)). Ultrafiltrates were 
collected in 5 ml polyethylene (PE) tubes, which prior to 
cent~fugation were pretreated in order to minimize pep- 
tide adsorption: the tubes were filled with 2 g/l HSA 
dissolved in purified water and left for 2 h at room tem- 
perature. After emptying 0.250 ml HSA solution was 
added to each tube and the content lyophilized. 
2.21. Sample coi~ectio~. Collection of ultra~trate 
must be initiated at a time when the IGF flux across the 
membrane is constant. However, some early non-specific 
adsorption of peptide to the YMT membrane and sup- 
porting device was observed: the concentration of IGF-I 
in the ultrafiltrate increased during the first 40 min, fol- 
lowed by a constant level in the intervals from 40 to 70, 
40 to 100 and 40 to 130 min of centrifugation. Two 
typical profiles are shown in Fig. 1A. Pretreatment of the 
filters with insulin and/or Tween-20 did not further 
change this profile. 
2.2. Ce~tr~~~gation pr cedure 
The method of separating free from bound IGF was 
based on ultrafiltration by centrifugation. Amicon YMT 
30 membranes and MPS-1 supporting devices were used 
2.2.2. Sample volume. The relation between the ap- 
plied sample volume, ultrafiltrate volume, and the result- 
ing IGF-I content was investigated. For two sera 4 vol- 
umes (0.4, 0.6, 0.8 and 1.0 ml) were centrifuged and the 
ultrafiltrate corresponding to the interval 40 to 100 min 
collected. Fig. 1B shows the results from one of the sera. 
For both sera tested, sample volumes between 0.4 and 
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Fig. 1. (A) Sample collection: for each of the two profiles the 4 columns represent he IGF-I concentration obtained in the ultratiltrates after 0 to 
40,40 to 70,40 to 100 and 40 to 130 min of centrifugation, respectively. (B) Influence of sample volume on ultrafiltrate volume (circles; right Y axis) 
and IGF-I concentration (columns; left Y axis). Values are means + S.E.M.. 
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Fig. 2. Influence of (A) temperature and (B) sample pH on the concentration of free IGF-I in the ultrafiltrates for two sera obtained from healthy 
volunteers. (C) The influence of dilution in KBB (solid lines) in serum from two healthy volunteers (m and l ), one acromegalic patient (A) and one 
growth hormone deficient subject (v). For comparison of the influence of ionic milieu on the concentration of free IGF-I, the two sera from the healthy 
volunteers were also diluted in Tris buffer (broken lines). All values are means f S.E.M., where S.E.M. exceeds the size of the symbol. (D) Free IGF-I 
was separated from bound using HPLC. Three different flows were chosen: 0.25 ml per min (solid line), 0.5 ml per min (broken line) and 1 .O ml per 
min (dotted line). The IGF-I standard eluted in fraction 36 to 44 (solid bar). 
0.8 ml resulted in similar ultrafiltrate volumes and IGF-I 
concentrations. Hence a sample volume of 0.5 ml was 
chosen for further experiments. 
2.2.3. Analytical recovery. Recovery studies of ex- 
ogenous IGF were performed in newborn calf serum 
containing only small amounts of endogenous IGF (total 
IGF-I -30&l and total IGF-II < 2pg/l). IGF-I (940&l) 
and IGF-II (600 &l) were added to serum, centrifuged 
and the ultrafiltrate and concentrate (above the filter) 
analyzed for IGF-I and IGF-II. The volume of the ul- 
tra&rate (determined by weight) averaged 121 f 8 ~1 
(0 to 40 min, n = 9), 20 * 1 ,Ul (40 to 70 min, n = 3) 
32 f 4 @(40 to 100 min, n = 3), and 46 + 7 ,~A(40 to 130 
min, 12 = 3). In these intervals, the recovery of IGF-I in 
the ultra$ltrates was 37 f 3%, 89 + 7%, 105 f 2%, and 
105 + 9%, respectively; and of IGF-II 33 + 2%, 82 f 6%, 
83 f. 5%, and 76 + 15%, respectively. In the concen- 
trates, which were collected after 70, 100 and 130 min of 
centrifugation, the recovery of IGF-I averaged 143 k 2% 
and of IGF-II 116 + 2%. Based on these findings all 
further experiments were performed on ultrafiltrates col- 
lected in the interval from 40 to 100 min of centrifuga- 
tion. 
188 J. Frystyk et al.lFEBS Letters 348 (1994) I??-I9I 
2.2.4. Insulin-like growth factor binding proteins. The 
possible presence of IGFBPs in the ultrafiltrates was 
examined performing Western ligand blotting as de- 
scribed [17,18] on sera from 4 healthy volunteers: 2 ~1 
serum and 10 ~1 ultrafiltrate were analyzed. Serum 
samples yielded five bands of IGFBPs with apparent 
molecular weights of 3847 kDa (doublet) (-IGFBP-3), 
32 kDa (-IGFBP-2) 28 kDa (-IGFBP-l), and 24 kDa 
(-IGFBP4). Binding of 1251-IGF-II to these species 
in ligand blotting experiments was specific, since co-incu- 
bation of radioligand with unlabelled IGF-II led to dis- 
appearance of binding. In contrast, neither simple in- 
spection nor scanning (Shimadzu laser densitometer, 
model CS9OOlPC) of autoradiographed ultrafiltrates re- 
vealed any trace of IGFBPs. Immunoassays for IGFBP- 
1 (IGFBP- 1 ELISA, Medix Biochemica, Kainiainen, 
Finland: detecting limit 0.4 &l) and IGFBP-3 (IGFBP- 
3 RIA, Diagnostic System Laboratories Inc., Webster, 
TX, USA: detecting limit 1.0 &l) were also negative 
(data not shown). 
In addition, membrane retention of rhIGFBP-1 
(Medix Biochemica, Kainiainen, Finland) dissolved in 
newborn calf serum (130 ,@l) was examined. The con- 
centration of IGFBP-1 in the ultrafiltrates were read as 
0.3, 0.2 and 0.2 ,&l, respectively. Although below the 
detection limit given by the manufacturer of the assay 
(0.4 j&l) these results suggested a minimum retention of 
99.8%. 
2.3. Importance of re-establishing in vivo conditions 
before and during separation of free IGF 
2.3.1. Temperature. Two sera were centrifuged at 5, 
20, 34, 37, 40 and 45°C. Before ultrafiltration sera were 
incubated for 30 min at the centrifugation temperature, 
which was checked at 0, 40 and 100 min of centrifuga- 
tion. The result (Fig. 2A) demonstrates a strong, positive 
temperature dependency of free IGF-I and that mainte- 
nance of 37°C is critical. When compared to 37”C, the 
relative concentration of free IGF-I in the 2 sera was 
only 48% and 62% at 34°C and as much as 132% and 
176% at 40°C. At 5 and 20°C where separation of free 
and bound IGF takes places in most other techniques, 
the relative concentration was about 558% and 15-19%, 
respectively. 
2.3.2. Hydrogen ion concentration. Two sera were ad- 
justed to a range of pH-levels (2.0 to 9.0) using HCl or 
NaOH followed by incubation at 37°C for 30 min before 
centrifugation. After centrifugation, pH was measured 
again, and the final pH calculated as the mean of the two 
determinations (Fig. 2B). In both sera the concentration 
of free IGF-I followed a curve with nadir at pH 6, and 
with increasing concentrations at acid as well as alkaline 
pH levels. However, in the vicinity of pH 7.4 (from 7.27 
to 8.17) a fairly constant level of free peptide was ob- 
served. Hence, prior to further ultrafiltrations samples 
were adjusted to pH 7.4 with CO,. 
2.3.3. Ionic milieu and sample-dilution. Two normal 
sera (total IGF-I was 70 &l and 270 pg/l, respectively) 
were diluted l:l, 1:5, 1: 10 and 1: 20 in Krebs-Ringer 
bicarbonate buffer (KRB) (50 g/l HSA, pH was adjusted 
to 7.4 with CO,) and Tris-buffer (300 mmol/l, pH 7.4, 50 
g/l HSA). After dilution the samples were equilibrated 
for 30 min at 37°C. Within the investigated range, dilu- 
tion in KRB was virtually without any effect on the 
estimate of free IGF-I, whereas dilution in Tris-buffer 
increased the concentration several-fold (Fig. 2C). Also 
results in serum obtained from one GHD and one 
acromegalic patient (total IGF-I was 40 &l and 1140 
pg/l, respectively) were unaffected by dilution (Fig. 2C). 
2.3.4. Comparison of HPLC-separation and ultrajiltra- 
tion. HPLC was performed at room temperature on a 
Pharmacia Superdex 75-lo/30 column (Pharmacia Bio- 
technology, Sweden) eluted with 200 mmoY1 Tris, pH 
7.4, 6 g/l NaCl, 2 g/l HSA, 0.5% (w/v) NaN,, 0.1% (v/v) 
Tween-20 and 1.6 mg/l Titriplex V. Two sera from young 
healthy subjects (25 ~1 per sample) were chromatogra- 
phed using 3 different flow rates: 0.25,0.5 and 1.0 ml per 
min. Fractions of 250 ,ul corresponding to the elution of 
an IGF-I standard were collected and analyzed. For 
both sera immunoactive ‘free’ IGF-I eluted in strongly 
flow-dependent profiles; the result from one of the sera 
is shown in Fig. 2D. Hence, corresponding to a flow of 
0.25, 0.5 and 1.0 ml per min the estimated ‘free’ IGF-I 
was 6.6, 3.1 and 2.2 pg/l (serum 1) and 8.7, 4.0. and 
3.3 pg/l (serum 2). In contrast, free IGF-I as measured 
after ultrafiltration was 0.90 f 0.09 pg/l (serum 1) and 
1.18 + 0.04 pg/l (serum 2). 
2.4. Free IGF-I and IGF-II in different physiological and 
pathophysiological conditions 
The ultrafiltration method was evaluated by measur- 
ing free IGFs under ‘metabolic’ conditions. 
2.4.1. Oral glucose tolerance test (OGTT). After an 
overnight fast, an OGTT (75 g glucose dissolved in 150 
ml) was performed on one healthy subject. Venous blood 
samples (10 ml) were collected at every 15 min for the 
first 3 h, and every 30 min for the next 3 h. Samples were 
analyzed for free and total IGF-I and IGF-II, glucose 
(glucose oxidase method), insulin (an inhouse DELFIA 
assay performed as previously described [19,20]), growth 
hormone (hGH) (DELFIA hGH kit, Wallac Oy, Turku, 
Finland) and IGFBP-1 (Fig. 3A-C). The observed 
changes in serum glucose, insulin and hGH were as ex- 
pected. Total IGF-I and IGF-II were unchanged, being 
170 + 10 ,@l and 1,010 f 10 ,@l, respectively. Free 
IGF-I and IGF-II exhibited almost parallel changes, 
both in an inverse manner of IGFBP-1: from a basal 
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Fig. 3. The results from an oral glucose tolerance test are shown (A-C). (A) The changes in free IGF-I (a) and free IGF-II (0); (B) IGFBP-1 (0) 
and hGH (0); (C) glucose (0) and insulin (0). Values are means It S.E.M., where S.E.M. exceeds the size of the symbol. The CV averaged 32% for 
free IGF-I and 23% for free IGF-II. (D) Illustrates free IGF-I levels from growth hormone deficient subjects (GHD (e); n = 7), healthy volunteers 
(HV (w); n = 8) and 6 acromegalic patients (AC (A); n = 6). *P c 0.01 when compared to the other groups. (E) Shows the levels of free IGF-I (solid 
columns) and free IGF-II (open cohmms) in 49 healthy volunteers. *P < 0.05 when comparing free IGF-I levels in these groups to the youngest group 
(aged 20-29 years). Values are means k S.E.M. 
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level of about 250 rig/l (IGF-I) and 550 rig/l (IGF-II) 
both peptides increased about 2-fold to maximum values 
of 5.50 r&l (IGF-I) and 1,320 r&l (IGF-II). Levels of free 
IGF-II were significantly higher than time-matched free 
IGF-I levels (Wilcoxon paired non-parametric test; 
PC 0.001). Concomitant with the increase in free IGF a 
75% decrease in IGFBP-1 level was observed. Linear 
correlations were obtained between IGFBP-1 (independ- 
ent variable) and free IGF-I (equation: Y = 533-58X 
(P < 0.01); ? = 0.36) and free IGF-IL (equation: 
Y = 1174-135X (P c 0.05); 12 = 0.28). In addition, levels 
of free IGF-I (independent variable) and -11 correlated 
(equation: Y = 292 + 1.35X (P < 0.05); r2 = 0.26). 
2.4.2. Fasting in healthy subjects. Free and total IGF-I 
and IGF-II were determined in 8 healthy subjects after 
12 (overnight) and 60 h of fasting. During the extended 
fasting, IGFBP-1 levels increased from 2.6 + 0.3 ,@l 
(mean * S.E.M.) to 13.9 + 2.4 &l (PC 0.005). Total 
IGF-levels were unchanged (IGF-I: 160 * 20 &l (12 
h) vs. 150 If: 20 fig/l (60 h); IGF-II: 770 + 50 ,&l (12 h) 
vs. 810 f 60 pg/l (60 h). In contrast, a significant de- 
crease in levels of free IGF-I (620 + 110 rig/l (12 h) vs. 
290 It 60 rig/l (60 h); P c 0.05) and IGF-II (1,410 + 80 
rig/l (12 h) vs. 860 + 70 ngll (60 h); P <: 0.01) was ob- 
served. The CV of the free IGF-I and IGF-II determina- 
tions was 23%. 
2.4.3. Free IGF-I in growth hormone disorders. After 
an overnight fast the concentration of free IGF-I was 
measured in 6 acromegalic patients (total IGF-I: 490 to 
1,250 ,&l; free IGF-I: 1,530 to 8,490 rig/l)) and 7 GHDs 
(total IGF-I: 20 to 90 ,ug/l; free IGF-I: 50 to 440 rig/l)) and 
compared to the 8 healthy controls (total IGF-I: 110 to 
290 @g/l; free IGF-I: 220 to 1,200 r&l) (Fig. 3D). Despite 
some overlap between GHDs and healthy volunteers, the 
results were statistically different (P C 0.01 (non-par- 
ametric analysis of variance (Kruskal-Wallis) followed 
by Mann-jitney)). 
2.4.4. normal maternal. Finally, total and free IGF-I 
and IGF-II were measured (in duplicates) in 49 healthy 
subjects. They were grouped in 5 age intervals each con- 
taining between 8 and 10 subjects (Fig. 3E). Free IGF-I 
was 950 + 150 rig/l (20-29 years), 650 -f: 120 rig/l (30-39 
years), 560 rf: 90 n&l (40-49 years), 430 + 90 r&l (50-59 
years) and 410 4 70 rig/l (>60 years). Free IGF-I was 
significantly higher in the youngest group when com- 
pared to the 3 oldest (one way analysis of variance 
(ANOVA) followed by Duncan’s test for multiple com- 
parisons). However, when related to the total concentra- 
tion, the percentage of free IGF-I was similar in the 
5 groups: 0.38 4 0.02%. In contrast, free IGF-II was 
independent of age, being 1,480 + 80 rig/l (- 0.20 + 0.01% 
of total IGF-II). The CV of the single filtrations made 
on two different days was 33%. No correlations were 
found between free and total IGF levels, and between 
free IGF-I and free IGF-II. 
3. Discussion 
The method described is the first to isolate the free, 
unbound fractions of IGF-I and IGF-II under circum- 
stances close to in vivo conditions. As shown it is of 
crucial importance to maintain physiological tempera- 
ture, pH and ionic milieu; a finding in accordance with 
previous reports on determinations of free thyroid 
hormones [21,22]. The recovery in the ultrafiltrate of 
IGFs was between 80 and lOO%, and the ultrafiltrate 
contained no detectable IGFBPs. Furthermore, changes 
in sample constitution (above filter) were minor: less 
than one third of the sample volume was removed during 
centrifugation, accompanying a modest increase in pro- 
tein-content (1643%). This appears to have little or no 
impact on equilibrium as seen in Fig. 1A. It is notewor- 
thy that equilibria and ultrafiltrate concentrations have 
been shown to be unaltered during ultrafiltration by cen- 
trifugation for other protein-bound substances, even if 
the protein content is increased almost 2-fold [23]. 
The fraction of free IGFs has never unequivocally 
been demonstrated, but most studies find that the per- 
centage of free IGF-I in healthy subjects accounts for 
l-5% of total, extractable IGF-I [8,12,24]. Our results 
are considerably lower, being 0.38 + 0.02% (range 
0.14-& 76%). However, all previous studies were based 
on separation procedures precluding in vivo conditions 
and hence in vivo-like equilibria. 
The YMT membrane was selected among several can- 
didates because of its resulting high recovery and 
IGFBP-free ultrafiltrate. Despite a CV of 23 to 33% this 
method is capable of detecting changes in free IGFs 
during physiological metabolic challenges such as glu- 
cose loads and fasting and the observed inverse relation 
between free IGF-I (and IGF-II) and IGFBP-1 is in 
accordance with suggestions put forward by others on 
theoretical basis [ 1,251. Interestingly, the free peptide 
concentration seems to be a very sensitive indicator of 
early catabolism and growth hormone dysfunction and 
the obtained results suggest hat the concentrations of 
free IGF-I and IGF-II may have greater physiological 
and clinical relevance than the total concentrations. 
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